Extracellular ATP and CD39 activate cAMP-mediated mitochondrial stress response to promote cytarabine resistance in acute myeloid leukemia

Relapses driven by chemoresistant leukemic cell populations are the main cause of mortality for patients with acute myeloid leukemia (AML). Here, we show that the ectonucleotidase CD39 (ENTPD1) is upregulated in cytarabine (AraC)-resistant leukemic cells from both AML cell lines and patient samples in vivo and in vitro. CD39 cell surface expression and activity is increased in AML patients upon chemotherapy compared to diagnosis and enrichment in CD39-expressing blasts is a marker of adverse prognosis in the clinics. High CD39 activity promotes AraC resistance by enhancing mitochondrial activity and biogenesis through activation of a cAMP-mediated response. Finally, genetic and pharmacological inhibition of CD39 eATPase activity blocks the mitochondrial reprogramming triggered by AraC treatment and markedly enhances its cytotoxicity in AML cells in vitro and in vivo. Together, these results reveal CD39 as a new prognostic marker and a promising therapeutic target to improve chemotherapy response in AML. SIGNIFICANCE Extracellular ATP and CD39-cAMP-OxPHOS axis are key regulators of cytarabine resistance, offering a new promising therapeutic strategy in AML.

[1]  P. Puigserver,et al.  ER and Nutrient Stress Promote Assembly of Respiratory Chain Supercomplexes through the PERK-eIF2α Axis. , 2019, Molecular cell.

[2]  A. Roussel,et al.  Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. , 2019, Cell reports.

[3]  M. Carroll,et al.  Dexamethasone in hyperleukocytic acute myeloid leukemia , 2018, Haematologica.

[4]  G. Di Benedetto,et al.  Shaping mitochondrial dynamics: The role of cAMP signalling. , 2017, Biochemical and biophysical research communications.

[5]  R. Coutinho-Silva,et al.  Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor–Host Interaction and Therapeutic Perspectives , 2017, Front. Immunol..

[6]  M. Selak,et al.  Resistance Is Futile: Targeting Mitochondrial Energetics and Metabolism to Overcome Drug Resistance in Cancer Treatment. , 2017, Cell metabolism.

[7]  W. Parak,et al.  Maintenance of cellular respiration indicates drug resistance in acute myeloid leukemia. , 2017, Leukemia research.

[8]  D. Edwards,et al.  NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts. , 2017, Blood.

[9]  S. Fesik,et al.  MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. , 2017, Cell metabolism.

[10]  Eyal Gottlieb,et al.  Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemic stem cells , 2017, Nature Medicine.

[11]  M. Carroll,et al.  Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. , 2017, Cancer discovery.

[12]  Y. Hayashizaki,et al.  Bone Marrow Adipocytes Facilitate Fatty Acid Oxidation Activating AMPK and a Transcriptional Network Supporting Survival of Acute Monocytic Leukemia Cells. , 2017, Cancer research.

[13]  V. Imbert,et al.  Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy. , 2016, Blood.

[14]  John M. Ashton,et al.  Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche. , 2016, Cell stem cell.

[15]  Liping Zhang,et al.  Mitochondrial cAMP signaling , 2016, Cellular and Molecular Life Sciences.

[16]  Mark B. Carter,et al.  Cyclic AMP efflux inhibitors as potential therapeutic agents for leukemia , 2016, Oncotarget.

[17]  K. Yao,et al.  Carvedilol promotes mitochondrial biogenesis by regulating the PGC-1/TFAM pathway in human umbilical vein endothelial cells (HUVECs). , 2016, Biochemical and biophysical research communications.

[18]  J. Dipersio,et al.  Targeting the leukemia–stroma interaction in acute myeloid leukemia: rationale and latest evidence , 2016, Therapeutic advances in hematology.

[19]  M. Konopleva,et al.  Targeting leukemia's "fatty tooth". , 2015, Blood.

[20]  G. Ehninger,et al.  How I treat hyperleukocytosis in acute myeloid leukemia. , 2015, Blood.

[21]  J. Dick,et al.  AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress. , 2015, Blood.

[22]  C. Récher,et al.  A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia , 2015, Blood Cancer Journal.

[23]  N. Bec,et al.  Inhibition of CD39 Enzymatic Function at the Surface of Tumor Cells Alleviates Their Immunosuppressive Activity , 2014, Cancer Immunology Research.

[24]  M. Safa,et al.  cAMP protects acute promyelocytic leukemia cells from arsenic trioxide-induced caspase-3 activation and apoptosis. , 2014, European journal of pharmacology.

[25]  H. Dombret,et al.  Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis , 2014, British journal of haematology.

[26]  R. Ficarella,et al.  Regulation of the biogenesis of OXPHOS complexes in cell transition from replicating to quiescent state: involvement of PKA and effect of hydroxytyrosol. , 2014, Biochimica et biophysica acta.

[27]  M. Tsukimoto,et al.  Autocrine signaling via release of ATP and activation of P2X7 receptor influences motile activity of human lung cancer cells , 2014, Purinergic Signalling.

[28]  Purinergic signalling and cancer , 2013, Purinergic Signalling.

[29]  J. Eliaou,et al.  ENTPD1/CD39 is a promising therapeutic target in oncology , 2013, Oncogene.

[30]  P. Puigserver,et al.  PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. , 2013, Cancer cell.

[31]  Ø. Bruserud,et al.  Cyclic AMP can promote APL progression and protect myeloid leukemia cells against anthracycline-induced apoptosis , 2013, Cell Death & Disease.

[32]  R. Coutinho-Silva,et al.  Extracellular ATP induces cell death in human intestinal epithelial cells. , 2012, Biochimica et biophysica acta.

[33]  M. Smyth,et al.  CD73: a potent suppressor of antitumor immune responses. , 2012, Trends in immunology.

[34]  F. Di Virgilio,et al.  Purinergic signaling inhibits human acute myeloblastic leukemia cell proliferation, migration, and engraftment in immunodeficient mice. , 2012, Blood.

[35]  K. Baggerly,et al.  Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment. , 2010, Blood.

[36]  J. Tamburini,et al.  High levels of CD34+CD38low/−CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang (GOELAMS) study , 2011, Haematologica.

[37]  G. Giaever,et al.  Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. , 2011, Cancer cell.

[38]  J. Tellez,et al.  A role for nucleotides in support of breast cancer angiogenesis: heterologous receptor signalling , 2011, British Journal of Cancer.

[39]  H. Friess,et al.  Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer , 2011, Purinergic Signalling.

[40]  B. Löwenberg,et al.  Therapeutic advances in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  M. Carroll,et al.  Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. , 2011, The Journal of clinical investigation.

[42]  D. Scadden,et al.  The leukemic stem cell niche: current concepts and therapeutic opportunities. , 2009, Blood.

[43]  G. Burnstock,et al.  Purinergic receptor‐mediated effects of adenosine 5′‐triphosphate in urological malignant diseases , 2009, International journal of urology : official journal of the Japanese Urological Association.

[44]  A Bagg,et al.  A robust xenotransplantation model for acute myeloid leukemia , 2008, Leukemia.

[45]  Satoshi Tanaka,et al.  Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region , 2007, Nature Biotechnology.

[46]  S. Robson,et al.  Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice. , 2007, The American journal of pathology.

[47]  C. Müller,et al.  Contribution of E‐NTPDasel (CD39) to renal protection from ischemia‐reperfusion injury , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[48]  K. Klingel,et al.  Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury , 2007 .

[49]  J. Esteve,et al.  Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients. , 2005, Leukemia research.

[50]  Q. Waisfisz,et al.  High Stem Cell Frequency in Acute Myeloid Leukemia at Diagnosis Predicts High Minimal Residual Disease and Poor Survival , 2005, Clinical Cancer Research.

[51]  D. Gilliland,et al.  Drug therapy for acute myeloid leukemia. , 2005, Blood.

[52]  Peter E. M. Butler,et al.  P2Y purinergic receptors regulate the growth of human melanomas. , 2005, Cancer letters.

[53]  D. Erlinge,et al.  ADP Acting on P2Y13 Receptors Is a Negative Feedback Pathway for ATP Release From Human Red Blood Cells , 2005, Circulation research.

[54]  R. Scarpulla,et al.  Nuclear activators and coactivators in mammalian mitochondrial biogenesis. , 2002, Biochimica et biophysica acta.

[55]  M. Konopleva,et al.  Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins , 2002, Leukemia.

[56]  M. Schapira,et al.  Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. , 2001, Blood.

[57]  J. Boeynaems,et al.  Effects of extracellular nucleotides and nucleosides on prostate carcinoma cells , 2001, British journal of pharmacology.

[58]  V. Mootha,et al.  Mechanisms Controlling Mitochondrial Biogenesis and Respiration through the Thermogenic Coactivator PGC-1 , 1999, Cell.

[59]  C. Dixon,et al.  Extracellular nucleotides stimulate proliferation in MCF-7 breast cancer cells via P2-purinoceptors. , 1997, British Journal of Cancer.

[60]  E. Vellenga,et al.  Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. , 1987, Blood.